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of the gums. An increase in salivary IL-2 level most prob-
ably results from a micro-injury of oral mucosa following 
administration of cytostatics, which in turn may cause oral 
mucositis in children with ALL.
Keywords Children · ALL · Gingival Index · Saliva IL-2 
concentration
Introduction
Relations between immune response factors in saliva are 
especially important for maintenance of proper function 
of oral mucosa. Subjects undergoing chemotherapy often 
develop disorders in salivation and changes in salivary 
composition. Therefore, a tendency to inflammatory states 
developing within oral mucosa is often observed. Disorders 
of immunological balance lead to development of patho-
logical lesions on the oral mucosa defined as mucositis. 
Mucosal barrier injury (MBI) is a frequent and difficult-to-
treat complication of high-dose chemotherapy and radio-
therapy, as well as haematopoietic stem cell transplantation 
(HSCT) [1–4].
Oxidative stress is one of potential carcinogenic mecha-
nisms. This theory is based on studies in which free oxygen 
radicals may react with DNA, resulting in mutations that 
lead to neoplastic changes. On the other hand, reactive oxy-
gen species are factors inducing apoptosis in mutant cells. 
Therefore, paradoxically, increased activity of antioxidant 
defence may halt elimination of mutant cells and increase 
promotion of a neoplastic change. Oxidative stress may 
also play a role in modulation of immunological reactions 
by activating transcription factors that control IL-2, IL-10 
and TNF-α genes. Authors studying the effect of oxidative–
antioxidative balance disorders in children with ALL on 
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Purpose Subjects undergoing chemotherapy often develop 
disorders in salivation and changes in salivary composition. 
Therefore, a tendency to inflammatory states developing within 
oral mucosa is often observed. The objective of the study was 
to assess the effect of disturbed immunity on the gum condition 
in children with acute lymphoblastic leukaemia (ALL) dur-
ing anti-tumour treatment and to compare saliva interleukin-2 
(IL-2) concentration in relation to the condition of gums oral 
mucositis—must be removed in children with ALL.
Methods The study included 78 children with ALL in fol-
lowed three examinations and a control group included 78 
healthy children. Dental examination of the children with 
ALL and the control group included the evaluation of gin-
gival condition by gingival index (GI). Children’s unstimu-
lated saliva samples were taken, and IL-2 concentration 
was determined by Human IL-2 EIA.
Results Mean GI higher than 1 was observed in 3.17 % 
children with ALL. The results found higher frequency of 
gingival inflammations in children with ALL on chemo-
therapy compared with the healthy controls. A comparison 
of results for a given patient during anti-tumour therapy 
with regard to salivary IL-2 showed significant differences 
between examination 2 and examination 3. The results indi-
cated that IL-2 level in saliva was twice higher in a patient 
during chemotherapy.
Conclusions An increase in salivary level of the proin-
flammatory IL-2 cytokine in ALL children during chemo-
therapy may cause pathological changes in the condition 
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the level of extracellular cytokines IL-2, IL-4, IL-5, IL-10, 
TNF-α and INF-α in serum, observed increased IL-10 
level, higher TNF-α, IL-4, IL-5 and INF-γ levels in chil-
dren with ALL compared with healthy children [5].
Biological effects of IL-2 are induced by an IL-2 (IL-2R) 
receptor, which has three protein subunits: alpha, beta and 
gamma. The receptor exerts an indirect anti-tumour effect by 
activating NK cells, stimulating specific anti-tumour cyto-
toxicity and stimulating lymphokine-activated killers (LAK), 
which reveal non-specific and direct cytotoxic effect on can-
cerous cells. The basic IL-2 property is to activate effector 
cells to selective lysis of freshly isolated tumour cells. Apart 
from that, secondarily secreted cytokines, IL-1, IL-4 and 
IL-6, may also play a role here. The final result of this stimu-
lation increases expression of the receptor on the membrane 
of helper T cells, which produce IL-2 [6–8].
Purpose
The objective of the study was to assess the effect of disturbed 
immunity on the gum condition and saliva interleukin-2 (IL-2) 
concentration in children with acute lymphoblastic leukaemia 
(ALL) during anti-tumour treatment. The objective was also 
to compare saliva interleukin-2 concentration in relation to 
the Gingival Index (GI) reflecting condition of gums in chil-
dren suffering from acute lymphoblastic leukaemia.
Materials and methods
The study included 78 children aged from 2 to 18 years with 
acute lymphoblastic leukaemia (ALL) and a control group 
of 78 healthy children selected with the use of the analo-
gous method with regard to age and sex. In the group of 
examined children, five had recurrent neoplasms located in 
the brain and spinal cord, two children had recurrent bone 
marrow cancer, seven children had their CNS affected, and 
three children had Down’s syndrome. The examination of 
children with ALL followed three stages: examination 1 
performed prior to chemotherapy, examination 2 carried out 
from two days to five months following the onset of chem-
otherapy, examination 3 carried out after 0.5–1.5 years of 
anticancer therapy. Children with ALL were treated accord-
ing to ALLIC BFM 2002 programme and were qualified for 
three risk groups: standard risk (SR), intermediate risk (IR) 
and high risk (HR). Verification of risk groups took place 
on 8, 15 and 33 days of treatment by means of bone mar-
row examination and assessment of leukaemia blast count: 
M1 < 5 %, M2 5–25 %, M3 > 25 %, assessment of response 
to steroid treatment and assessment of leukocytosis.
The children were treated in the Department of Pediat-
ric Hematology and Oncology Medical University of Lub-
lin, with strict adherence to the appropriate protocols for 
risk groups, in which the successive days of treatment with 
certain medicines are administered. The Protocol I, which 
was performed in all children administered: dexamethasone 
(DEXA), vincristine (VCR), L-asparaginase (L-ASP), dau-
noribicin (DNR), cyclophosphamide (CPM), cytarabine 
(ARA-C), 6- mercaptopurine (6-MP), 6-thioguanine (6-TG) 
and methotrexate (MTX). The Protocol Mm was conducted 
in children with SR and IR group which was administered 
6-MP, MTX. Children with HR group immediately after the 
Protocol I had introduced HR blocks that used: DEXA, vin-
densin (VDS), DNR, HD MTX, ifosfamide  (IFO), L-ASP, 
HD ARA-C. Protocol II was then performed, which admin-
istered: VCR, doxorubicin (DOX), L-ASP, CPM, ARA-C, 
6-TG, MTX or Protocol III, which administered: VCR, 
DOX, L-ASP, CMP, ARA-C, 6-TG, MTX. The dose was 
dependent on the weight, height and age of patients.
Dental examinations were performed with basic diagnostic 
kits in artificial light. Clinical dental examination of the chil-
dren with ALL and the control group included the evaluation 
of gingival condition by gingival index (GI) (Löe and Silness). 
Table 1  Gingival conditions 
expressed as GI and saliva 
IL-2 concentration (in U/ml) in 
children with ALL and healthy 
controls
* Statistically significant value
Studied parameter Studied group of children X Me SD U Man–Whitney test
Z Significance level
GI ALL Examination 1 0.084 0.0 0.34 −2.5393 0.0111*
Examination 2 0.007 0.0 0.04 −0.2360 0.8134
Examination 3 0.017 0.0 0.13 −0.1928 0.8471
Healthy 0.003 0.0 0.03 The above values refer to 
healthy children
Saliva IL-2 ALL Examination 1 2.38 2.0 0.90 −1.6412 0.101
Examination 2 2.49 1.6 1.72 −0.1047 0.917
Examination 3 3.06 2.7 1.87 −3.1538 0.002*
Healthy 2.07 1.87 0.96 The above values refer to 
healthy children
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Two hours after morning meal, unstimulated saliva samples 
were taken and IL-2 concentration was determined by Human 
Interleukin-2 EIA DRG Diagnostics. The saliva samples were 
centrifuged for 15 min at 5000 rpm. Centrifuged saliva was 
frozen at −80 °C and stored until laboratory tests.
The results were analysed statistically. Measurable 
parameters were presented as means, medians, minimum, 
maximum and SD. U Man–Whitney test was used to com-
pare two independent groups; the Spearman R correla-
tion coefficient significance test was used to compare two 
quantitative traits and Wilcoxon’s test to compare depend-
ent groups. Statistical analysis was done by STATISTICA 
10.0; p < 0.05 was assumed statistically significant.
Results
The results of examinations in both groups and statistical 
analysis were listed in Table 1 and graphically presented on 
Fig. 1.
Gingival conditions were expressed as GI. In the group 
of children with ALL, mean GI determined in examination 
1 was 0.084 ± 0.34, in examination 2 GI = 0.007 ± 0.04 
and in examination 3 mean GI = 0.017 ± 0.13. In the group 
of healthy controls, GI = 0.003 ± 0.03. GI values were sta-
tistically significantly higher in the group with ALL prior to 
treatment in comparison with the control group (Table 1). 
In the group with ALL, GI determined in examination 1 
ranged 0–1 in 6.45 % children while GI > 1 was noted in 
4.84 % children. In this group, mean GI determined over 1- 
to 5-month period of treatment was higher compared with 
the control group; however, the differences between those 
groups were not statistically significant. Mean GI > 1 was 
observed in 3.17 % children with ALL in examination 2. 
It can be explained by the fact that gingival inflammations 
occurred in that period with lesser frequency compared 
with examination 1. In examination 3, the children with 
ALL had higher GI in comparison with the control group; 
the differences were statistically insignificant though. Simi-
lar to examination 2, GI > 1 was noted in 3.17 % children 
with ALL. The results found higher frequency of gingi-
val inflammations in children with ALL on chemotherapy 
compared with the healthy controls (Table 1).
Saliva concentration of interleukin-2 (IL-2) determined 
in the group of children with ALL in examination 1 ranged 
1.01–4.57 U/ml. In that group in examination 1, mean 
saliva IL-2 concentration was 2.38 ± 0.90 U/ml. In the 
group of healthy children, saliva IL-2 concentration ranged 
0.32–4.96 U/ml and mean saliva IL-2 concentration was 
2.07 ± 0.96 U/ml. Mean saliva IL-2 concentrations (exami-
nation 1) were higher in the group of children with ALL in 
comparison with the healthy controls; however, the differ-
ences were not statistically significant (p > 0.05; Table 1).
In examination 2, saliva IL-2 concentrations ranged 
0.39–8.86 U/ml; mean saliva IL-2 concentration was 
2.49 ± 1.72 U/ml. In the group of children with ALL, mean 
saliva IL-2 values were higher compared with examination 
1 and with the control group; however, the differences were 
statistically insignificant (p > 0.05; Table 1).
In examination 3, saliva IL-2 concentrations ranged 
0.17–8.86 U/ml; mean saliva IL-2 concentration was 
3.06 ± 1.87 U/ml. In the group of children with ALL, mean 
saliva IL-2 values were statistically significantly higher 
compared with the control group (p = 0.002; Table 1).
Fig. 1  Salivary interleukin 2 
(IL-2) concentration in children 
with ALL in subsequent exami-
nations (U/ml)
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A comparison of results for a given patient during anti-
tumour therapy with regard to salivary IL-2 showed signif-
icant differences between study 2 and study 3 (Wilcoxon 
signed-rank test; Z = 2.173; p = 0.0297). The results indi-
cated that IL-2 level in saliva was twice higher in a patient 
during chemotherapy. The findings were also confirmed by 
a logistic regression model (logit): total loss: 56.4033, χ2 
(3) = 9.5925 (p = 0.02238) (Fig. 1).
With regard to the risk group, the analysis of saliva 
IL-2 levels in ill children showed a statistically significant 
correlation between the average value for this cytokine 
and the risk group of children with ALL in study 1 (Spear-
man’s rank correlation coefficient = 0.5546, t = 2.4941, 
p = 0.0258) and in study 2 (Spearman’s rank correlation 
coefficient = 0.3988, t = 2.4983, p = 0.0176). In study 1, 
the lowest IL-2 values in saliva were observed in children 
of the SR group 2.29 ± 0.65 U/ml, and the highest aver-
age IL-2 values in saliva were observed in children of the 
HR group 2.44 ± 0.99 U/ml. In study 2, children from the 
group of SR had the highest IL-2 value and the difference 
between the groups was statistically significant. In study 
3, children from the group of HR had again the highest 
IL-2 level in saliva, i.e. 3.74 ± 1.52 U/ml, although dif-
ferences between the groups were close to statistical 
significance.
In the group of ALL children, a statistical analysis of 
the findings did not show significant correlations between 
GI and salivary IL-2 in study 1, study 2 and study 3. How-
ever, a GI increase was accompanied by an increase in 
saliva IL-2 in study 1 ((Spearman’s rank correlation coef-
ficient = 0.2276, t = 1.4596, p = 0.1524) and 3 (Spear-
man’s rank correlation coefficient = 0.2251, t = 1.7445, 
p = 0.0864), which may mean that gingival inflammation 
is accompanied by an increase in the proinflammatory 
cytokine level. In study 2, a decreased GI level was accom-
panied by a lower level of saliva IL-2 (Spearman’s rank 
correlation coefficient = 0.0425 t = 0.2787, p = 0.7818).
Discussion
In recent years, saliva has been more and more frequently 
used to assess biomarkers in various, sometimes serious, 
diseases. Comparative studies indicate that saliva may 
become an alternative tool to blood serum in assessment of 
certain biomarkers. Due to a non-invasive method of mate-
rial collection, saliva is a good tool to diagnose various dis-
eases. It enables assessment of treatment, as well as moni-
toring patients after treatment with little discomfort for 
both the patient and the physician. The use of non-invasive 
techniques is especially important when the patients suffer 
not only from the primary disease but also from its compli-
cations [9–11].
Studies confirm that certain salivary biomarkers, i.e. 
IFN-γ, IL-1-β1, TNF-α, IL-6, IL-4 and IL-8, may be used 
for predicting future development of periodontal diseases. 
Immunoregulatory mechanisms of cytokines involved in 
inflammations, infectious and immunological diseases in 
the oral cavity play a special role in protecting the host and 
maintaining oral homoeostasis. Saliva may become a good 
material to detect proinflammatory markers in the oral cav-
ity [12, 13]. In the future, levels of salivary cytokines may 
play an important role as replacement biomarkers in assess-
ing chemotherapy efficacy. Proinflammatory cytokines 
occurring in saliva may have a diagnostic and prognostic 
value in the future, acting as replacement markers of neo-
plastic transformation [14].
Research is also conducted to highlight the importance 
of measuring salivary cytokines to assess the risk of oral 
health and disease in adolescence and raise important ques-
tions about the role of salivary cytokines in intracellular 
and hormonal signalling. Patients undergoing chemo- and 
radiotherapy are especially exposed to salivation disorders. 
At the moment of salivary gland dysfunction, the majority 
of protective properties of saliva are absent [15].
Our study revealed a higher level of salivary IL-2 in 
children with ALL as compared to the control group and 
a significant increase in the average cytokine value dur-
ing the anti-tumour treatment. Significant differences were 
observed in IL-2 levels with regard to the risk group of 
ALL children. In study 1, the lowest levels of saliva IL-2 
were observed in children of the SR group and the highest 
average values of saliva IL-2 were recorded in children of 
HR group. Also in study 3, the children of the HR group 
had the highest average IL-2 value in saliva.
Du et al. [16] found that serum concentrations of H2S, 
IL-1β, IL-6, IL-10 and MIP-1α in children with ALL 
increased significantly. Meanwhile, serum concentrations 
of IL-2, TNF-α, IFN-γ and IL-4 decreased. After chemo-
therapy, concentrations of H2S and IL-10 decreased sig-
nificantly, but IL-4 and IFN-γ concentrations increased 
markedly. At remission stage, serum concentrations of H2S, 
IL-1β, IL-4, IL-6, IL-10 and MIP-1α further decreased sig-
nificantly, and those of IL-2, TNF-α and IFN-γ increased 
again. All these results suggest that H2S and cytokines are 
involved in immune regulatory process of children with ALL 
with chemotherapy, which is consistent with this report. 
Motowi et al. [17] suggested that measurement of serum 
sHLA-G might be helpful in diagnosis of ALL, while sIL-2R 
might be useful in diagnosis and follow-up of ALL in pae-
diatric patients. Research carried out in order to search for 
new more effective treatments for patients with ALL, seems 
inclined to use the immune response factors, such as NK in 
the presence of clinical grade IL-2 and IL-15 [18].
Studies in which authors were comparing the level of 
proinflammatory cytokines (TNF-α, IL-1a, IL-6 and IL-8) 
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in saliva of patients with oral squamous cell carcinoma 
and patients with precancerous condition of the oral cavity 
as well as healthy patients, revealed an increased level of 
these cytokines in saliva of patients with squamous cell car-
cinoma. The level of proinflammatory cytokines was also 
increased in subjects with a precancerous condition of the 
oral cavity in comparison with the control group [14].
Due to the general condition of the patients with ALL, 
there is an increased risk of inflammation in the first section 
of the gastrointestinal tract. Therefore, a special emphasis 
must be placed on prophylactics and oral hygiene. Physi-
cians agree that the most important factor lowering the risk 
of oral complications is regular, at least twice-daily tooth 
brushing, mouth washing and effective motivation of the 
patient to clean dental surfaces and soft oral tissues [3, 19, 
20].
Summary
A statistically significantly higher level of gingival inflam-
mation markers was observed in ALL children in com-
parison with the control group. Mean saliva IL-2 level in 
children with ALL was higher and statistically significantly 
increasing during chemotherapy in comparison with chil-
dren of the control group. In the ALL group, the highest 
IL-2 level was observed in the HR group and the tendency 
was also present in the final stage of treatment.
Conclusions
Overall, these findings suggest that the condition of gums 
and oral mucosa in children with ALL was not satisfac-
tory during chemotherapy. An increase in salivary level of 
the proinflammatory IL-2 cytokine in ALL children during 
chemotherapy may cause pathological changes in the con-
dition of the gums and potentiation of oral mucositis. An 
increase in salivary IL-2 level most probably results from 
a micro-injury of oral mucosa following administration of 
cytostatics, which destroy quickly dividing cells, which in 
turn may cause oral mucositis in children with ALL.
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